The 2027 Global Prostate Cancer Congress

Where Evidence Meets Practice

January 9–12, 2027 at The Grand Hyatt Deer Valley in Park City, Utah

The LUGPA 2027 Global Prostate Cancer Congress provides a comprehensive overview of best practices in the prevention, detection, management, and treatment of prostate cancer. The program is designed by LUGPA as a live, in-person meeting to serve an audience of urology and oncology learners. This continuing medical education program has been designed to cover the latest research and cutting-edge topics in prostate cancer—including PSA screening, precision oncology, advanced imaging, active surveillance, and emerging therapies—while offering an opportunity to ski and enjoy resort activities in Park City.

REGISTRATION OPENS HERE SEPTEMBER 9

A limited number of FREE registration slots will be available to members of LUGPA group practices on a first-come, first-served basis. When those limited complimentary registration slots are filled, seats for this event will be available to LUGPA members at a discounted rate [members $500 and non-members: $800].

Registration will open on September 9 for members of LUGPA group practices to attend. Mark your calendar to claim one of the 50 complimentary registrations before they fill up!

Join colleagues from across the country for an important gathering focused on bringing evidence-based insights back to your practice on Monday morning. Don’t miss this opportunity to connect, learn, and experience Deer Valley.

Preliminary Agenda

CME Details

Last year, this activity offered more than 9 AMA PRA Category 1 Credits™. This year’s activity is being planned and developed for a similar number of AMA PRA Category 1 Credits™. The final number of credits will be announced once accreditation is confirmed. The total number of credits available will be based on the overall hours of accredited education offered during the program. Attendees will be able to claim credit reflecting their participation.

Save the date: Call for Abstracts Opens SOON.

LUGPA will soon accept abstracts for the 2027 Global Prostate Cancer Congress.

We will welcome submissions from members, non-members, residents, and industry professionals on topics including:

Clinical strategies for managing prostate cancer
Original research or outcomes data
Novel treatments or technologies
Case-based learning

Accepted presenters will be invited to submit a 2–3 minute video of their abstract to be played during the meeting—no need to attend in person.

Full submission guidelines and access to the portal will open soon.

Questions?
If you have any questions, please contact Katherine Stack, [email protected].
Industry partners who have questions can contact Rachel Rusch, [email protected].

Want to receive a sponsorship prospectus for a LUGPA event?
Contact Rachel Rusch at (312) 890-3167 or [email protected].

>>>>>>>>>>>>>>>>>>>>>>>>>>>>

RECAP of the 2026 Global Prostate Cancer Congress

Highlights from the 2026 LUGPA Global Prostate Cancer Congress

	The learning begins at our Global Prostate Cancer Congress #LUGPAgpcc today. Program chair: E. David Crawford, MD welcomes the attendees and kicks off the CME sessions. pic.twitter.com/3yZ5NdctXU — LUGPA (@UrologyUS) January 11, 2026

The 2026 LUGPA Global Prostate Cancer Congress brought urology and oncology leaders together January 10–13 at the Grand Hyatt Deer Valley in Park City, Utah, for three days of education, collaboration, and connection focused on the full continuum of prostate cancer care.

Designed by LUGPA in collaboration with Specialty Networks, the program delivered evidence-based updates and practical insights spanning prevention, diagnosis, treatment, survivorship, and health policy. Sessions explored integrated cancer care models, the role of diet and the microbiome, APP-directed clinics, caregiver and patient perspectives, and strategies to enhance the patient and provider journey.

Clinical highlights included advances in diagnostics and imaging—such as PSMA-guided approaches, novel PET tracers, MRI, AI-supported pathology, and biomarker-driven testing—as well as in-depth discussions on genetics and genomics, localized and hormone-sensitive disease, and next-line therapies for castration-resistant prostate cancer, including radioligand therapy and PARP inhibitors. Dedicated sessions also addressed ADT side-effect management, cardio-oncology considerations, and survivorship.

The agenda balanced cutting-edge science with real-world application through expert panels, point-counterpoint debates, case discussions, and selected abstract presentations. Industry-supported symposia, exhibit hall programming, and networking events—including Industry Night—provided additional opportunities for engagement and peer connection. With built-in free time to enjoy the Deer Valley winter setting, the Congress delivered a distinctive blend of high-level education, meaningful dialogue, and collegial networking.

Photos from the meeting can be found on social media using #LUGPAgpcc, and educational content from the Congress will be made available on LUGPALearn in the coming months.